Any pro-life philanthropist wanting to save as many as possible of the world's unborn could do no better than to put his money into developing technologies that would allow sex selection before conception.
By multiplying drug candidates, robochemistry ought to allow researchers the luxury of selection, putting to trial only those compounds that are the most likely to succeed.